GeneDx Reports Strong Q4 & Full Year 2025 Results, Exceeding Guidance and Reaffirming Positive 2026 Outlook
Summary
GeneDx reported strong Q4 and full year 2025 financial results, meeting or exceeding all key guidance metrics, driven by significant growth in its core genomic testing business and a substantial improvement in adjusted net income, while also reaffirming positive 2026 guidance.
Key Events
-
Strong Q4 and Full Year 2025 Financial Performance
Reported Q4 2025 revenues of $121.0 million (up 27% YoY) and full year 2025 revenues of $427.5 million (up 41% YoY). Exome and genome test revenue grew 32% in Q4 and 54% for the full year.
-
Met or Exceeded All Key 2025 Guidance Metrics
The company met its full year 2025 guidance for total revenue, exome and genome revenue growth, exome and genome volume growth, and adjusted gross margin.
-
Significant Improvement in Adjusted Net Income
Full year 2025 adjusted net income reached $41.8 million, a substantial increase from $9.4 million in full year 2024, indicating improved operational efficiency and profitability on an adjusted basis.
-
Reaffirmed Positive Full Year 2026 Guidance
Management reaffirmed its full year 2026 guidance, expecting revenues of $540 to $555 million, 33-35% growth in exome and genome revenue and volume, and positive adjusted net income.
Analysis
GeneDx Holdings Corp. delivered a robust financial performance for both the fourth quarter and full year 2025, consistently meeting or exceeding its own guidance across key metrics. The company demonstrated significant growth in its core exome and genome testing business, with full-year revenue increasing by 41% and exome/genome test revenue growing by 54% year-over-year. Notably, adjusted net income for the full year 2025 saw a substantial improvement to $41.8 million, up from $9.4 million in the prior year, signaling a positive trajectory towards profitability on an adjusted basis. The reaffirmation of strong 2026 guidance, including continued revenue and volume growth and positive adjusted net income, provides a clear and optimistic outlook for investors. Additionally, the company raised $21.1 million through an At-The-Market offering in Q4 2025, bolstering its cash position.
At the time of this filing, WGS was trading at $84.26 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $55.17 to $170.87. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.